Patents Assigned to Intellikine LLC
  • Patent number: 10172858
    Abstract: The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: January 8, 2019
    Assignee: INTELLIKINE LLC
    Inventors: Yi Liu, Pingda Ren, Katayoun Jessen, Xin Guo, Christian Rommel
  • Patent number: 9828378
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: November 28, 2017
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
  • Patent number: 9822131
    Abstract: Chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with P13 kinase activity are described herein.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 21, 2017
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Katrina Chan, Christian Rommel, Liansheng Li
  • Patent number: 9790228
    Abstract: Provided herein are compounds of formula (I-A), (I-B), (I-C), or (I-D), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: October 17, 2017
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
  • Patent number: 9682141
    Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: June 20, 2017
    Assignee: Intellikine LLC
    Inventors: Katayoun Jessen, Xin Guo, Pingda Ren, Christian Rommel, Yi Liu
  • Patent number: 9669032
    Abstract: The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: June 6, 2017
    Assignee: Intellikine LLC
    Inventors: Yi Liu, Lynne Bui, Michael Martin, Troy Edward Wilson, Christian Rommel
  • Patent number: 9655892
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: May 23, 2017
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • Patent number: 9637492
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: May 2, 2017
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan
  • Patent number: 9522146
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: December 20, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • Patent number: 9403820
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3K activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3K activity, are described herein.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: August 2, 2016
    Assignees: Intellikine LLC, Sigma-Aldrich Company Limited
    Inventors: Pingda Ren, Michael Martin, Christopher Peter Worrall, Susanna del Rio Gancedo
  • Patent number: 9359349
    Abstract: The present invention provides compounds of Formula I that modulate PI3 kinase activity and methods of treatment of diseases and conditions associated with PI3 kinase activity.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: June 7, 2016
    Assignee: INTELLIKINE LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson
  • Patent number: 9359352
    Abstract: The present invention provides substituted benzimidazole compounds of Formula I: wherein the variables R1, R2, W1, W2, W3, W4, W5, W6, Wa, Wb, Wc and Wd are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 7, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Patent number: 9345706
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 24, 2016
    Assignee: Intellikine, LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan
  • Patent number: 9315505
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: April 19, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Troy Edward Wilson
  • Patent number: 9295673
    Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: March 29, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Katayoun Jessen, Xin Guo, Christian Rommel, Troy Edward Wilson
  • Patent number: 9296742
    Abstract: Provided herein are compounds of formula (I-A), (I-B), (I-C), or (I-D), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: March 29, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
  • Patent number: 9216982
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: December 22, 2015
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • Patent number: 9206182
    Abstract: Substituted isoquinolin-1(2H)-one compounds that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: December 8, 2015
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • Patent number: 9174994
    Abstract: The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: November 3, 2015
    Assignee: Intellikine, LLC
    Inventors: Yi Liu, Lynne Bui, Michael Martin, Troy Edward Wilson, Christian Rommel
  • Patent number: 9127000
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: September 8, 2015
    Assignee: Intellikine, LLC.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell